Genitourinary Cancers Symposium (ASCO GU)

Induction ipilimumab plus nivolumab followed by consolidative chemoradiotherapy led to bladder preservation in stage 2/3 urothelial carcinoma of the bladder.

SBRT plus nivolumab and ipilimumab did not improve PFS vs the dual checkpoint inhibitor regimen alone in advanced RCC.

Toni K. Choueiri, MD, discusses data from the phase 3 LITESPARK-022 trial in ccRCC after nephrectomy.

Deep and durable responses were maintained with cabozantinib plus nivolumab in long-term follow-up of the CheckMate 9ER trial.

Pembrolizumab plus belzutifan reduced the risk of having a DFS event by 28% vs pembrolizumab alone in high-risk clear cell RCC.

Andrea Necchi, MD, discusses final data from the SunRISe-2 study of the gemcitabine intravesical system plus cetrelimab in MIBC.

Belzutifan plus lenvatinib significantly prolonged PFS and showed a trend toward improved OS vs cabozantinib in advanced ccRCC after anti–PD-L1 therapy.

In SunRISe-2, Gem-iDRS plus cetrelimab did not improve BI-EFS vs chemoradiotherapy in bladder-sparing MIBC and the trial stopped early for futility.

Ravi A. Madan, MD, discusses data from a phase 2 trial of enzalutamide monotherapy in patients with biochemically recurrent prostate cancer.

An analysis of RETAIN-1 and RETAIN-2 showed ctDNA was prognostic for metastatic recurrence in MIBC.

Adding cabazitaxel to ADT and radiotherapy did not improve PFS or MFS vs SOC after 7 years among patients with high-risk localized prostate cancer.

Disitamab vedotin elicited response rates over 50% in previously treated HER2-expressing advanced urothelial carcinoma.

Perioperative enfortumab vedotin plus pembrolizumab improved EFS and OS in cisplatin-eligible muscle-invasive bladder cancer.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

The alpha-emitting radionuclide actinium-225 was well tolerated and produced PSA responses across all dose levels in patients with mCRPC.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.

Long-term follow-up data from PEACE-3 showed enzalutamide plus radium-223 improved OS and rPFS in patients with mCRPC and bone metastases.

Enrique Gallardo, MD, discusses final OS data from the phase 3 PEACE-3 trial of radium-223 with/without enzalutamide in mCRPC.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.

The addition of capivasertib to abiraterone elicited an rPFS advantage and preserved QOL compared with placebo plus abiraterone in PTEN-deficient mHSPC.

Abiraterone acetate, prednisone, and olaparib combination therapy boosted efficacy outcomes in first-line mCRPC.

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.

Experts preview key prostate cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.

Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.

A phase 3 study will be initiated after completion of the first neoadjuvant phase 2 trial of platinum-based chemotherapy plus immunotherapy in UTUC.